HEMOSTEMIX INC (HEM.CA) Stock Overview
TSX-V:HEM - CA4236943060 - Common Stock
HEM.CA Key Statistics, Chart & Performance
The current stock price of HEM.CA is 0.105 CAD. In the past month the price increased by 5%. In the past year, price increased by 40%.
HEM.CA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| EDT.CA | SPECTRAL MEDICAL INC | N/A | 448.74M | ||
| FRX.CA | FENNEC PHARMACEUTICALS INC | N/A | 343.14M | ||
| EPRX.CA | EUPRAXIA PHARMACEUTICALS INC | N/A | 269.70M | ||
| TH.CA | THERATECHNOLOGIES INC | N/A | 205.30M | ||
| HBP.CA | HELIX BIOPHARMA CORP | N/A | 102.35M | ||
| WLLW.CA | WILLOW BIOSCIENCES INC | N/A | 97.56M | ||
| MDNA.CA | MEDICENNA THERAPEUTICS CORP | N/A | 88.41M | ||
| BLU.CA | BLUENERGIES LTD | N/A | 82.42M | ||
| NRX.CA | NUREXONE BIOLOGIC INC | N/A | 65.61M | ||
| COV.CA | COVALON TECHNOLOGIES LTD | 18.15 | 64.71M | ||
| MSCL.CA | SATELLOS BIOSCIENCE INC | N/A | 62.21M | ||
| SVA.CA | SERNOVA BIOTHERAPEUTICS INC | N/A | 45.90M |
Related stock screener links
About HEM.CA
Company Profile
Hemostemix, Inc. is a clinical-stage biotechnology company, which is focused on developing and commercializing a proprietary autologous cell therapy to treat ischemic diseases. The company is headquartered in Calgary, Alberta. The company went IPO on 2012-12-20. The firm has developed, patented, and is scaling and selling autologous (patient’s own) blood-based stem cell therapies that include angiogenic cell precursors (ACP-01), later neural cell precursors (NCP-01), and cardiomyocyte cell precursors (CCP-01). The company holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including ACP-01, CCP-01 and NCP-01. ACP-01 is a clinically relevant and statistically significant treatment for peripheral arterial disease, chronic limb-threatening ischemia, non-ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure, and angina. The company has completed a Phase II clinical trial for chronic limb-threatening ischemia. The company has two wholly owned subsidiaries, Kwalata Trading Limited and PreCerv Inc. PreCerv Inc. holds a global field of use license to ACP-01 & NCP-01 for the treatment of conditions of the central and peripheral nervous system.
Company Info
HEMOSTEMIX INC
707 7th Ave. SW, Suite 1150
Calgary ALBERTA T2P 3H6 CA
CEO: Thomas Smeenk
Employees: 9
Phone: 19055804170
HEMOSTEMIX INC / HEM.CA FAQ
What is the stock price of HEMOSTEMIX INC today?
The current stock price of HEM.CA is 0.105 CAD. The price decreased by -4.55% in the last trading session.
What is the ticker symbol for HEMOSTEMIX INC stock?
The exchange symbol of HEMOSTEMIX INC is HEM and it is listed on the TSX Venture Exchange exchange.
On which exchange is HEM.CA stock listed?
HEM.CA stock is listed on the TSX Venture Exchange exchange.
What is HEMOSTEMIX INC worth?
HEMOSTEMIX INC (HEM.CA) has a market capitalization of 19.08M CAD. This makes HEM.CA a Nano Cap stock.
How many employees does HEMOSTEMIX INC have?
HEMOSTEMIX INC (HEM.CA) currently has 9 employees.
What are the support and resistance levels for HEMOSTEMIX INC (HEM.CA) stock?
HEMOSTEMIX INC (HEM.CA) has a support level at 0.08 and a resistance level at 0.12. Check the full technical report for a detailed analysis of HEM.CA support and resistance levels.
Should I buy HEMOSTEMIX INC (HEM.CA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of HEM.CA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of HEM.CA, evaluating the profitability, health, valuation and growth aspects
- HEMOSTEMIX INC (HEM.CA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- HEMOSTEMIX INC (HEM.CA) Sales and EPS estimates to see what analysts future expectations are.
- HEMOSTEMIX INC (HEM.CA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- HEMOSTEMIX INC (HEM.CA) Insider and Institutional Ownership to learn about the owners and their transactions.
- HEMOSTEMIX INC (HEM.CA) Stock Chart to make your own analysis
- HEMOSTEMIX INC (HEM.CA) Latest news and press-releases to stay up to date.
Does HEMOSTEMIX INC (HEM.CA) stock pay dividends?
HEM.CA does not pay a dividend.
When does HEMOSTEMIX INC (HEM.CA) report earnings?
HEMOSTEMIX INC (HEM.CA) will report earnings on 2025-09-01.
What is the Price/Earnings (PE) ratio of HEMOSTEMIX INC (HEM.CA)?
HEMOSTEMIX INC (HEM.CA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.03).
HEM.CA Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to HEM.CA. When comparing the yearly performance of all stocks, HEM.CA turns out to be only a medium performer in the overall market: it outperformed 64.8% of all stocks.
HEM.CA Financial Highlights
Over the last trailing twelve months HEM.CA reported a non-GAAP Earnings per Share(EPS) of -0.03. The EPS decreased by -80.42% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -278.86% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |